Interestingly, more than a handful of the funds listed in the list of zombies are life science and healthcare-related funds.
As someone running a biotech startup, this is rather relevant to me...
It occurs to me that the cutoff of 6 months since last round may be a bit short for the life science world, where funds tend to make fewer, bigger investments with lower frequency.
It's also interesting to note that a few strategic venture funds are listed (Novartis stuck out at me) and that these guys might not fit the same mod, given that they invest with eye on relevance to the mothership.
With those two caveats in mind, there are also some indicators to suggest that early stage investing in biotech/life-science startups has been slowing down over the last few years. There was a big of a boom prior to this, but it's fairly widely acknowledged that there haven't been good returns for the billions of dollars poured into early-stage biotech companies. There's now a bias toward larger series A's on slightly lower risk startups...
I would be happy to make you another list that has 12 month cutoff, would that help? We were discussing last night whether health/biotech funds have a different cycle than web tech, would love to know your thoughts on that.
As someone running a biotech startup, this is rather relevant to me...
It occurs to me that the cutoff of 6 months since last round may be a bit short for the life science world, where funds tend to make fewer, bigger investments with lower frequency.
It's also interesting to note that a few strategic venture funds are listed (Novartis stuck out at me) and that these guys might not fit the same mod, given that they invest with eye on relevance to the mothership.
With those two caveats in mind, there are also some indicators to suggest that early stage investing in biotech/life-science startups has been slowing down over the last few years. There was a big of a boom prior to this, but it's fairly widely acknowledged that there haven't been good returns for the billions of dollars poured into early-stage biotech companies. There's now a bias toward larger series A's on slightly lower risk startups...